Cantor Fitzgerald initiated coverage of Pharvaris (PHVS) with an Overweight rating and $28 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
- Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
- Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
- Pharvaris Reports 2024 Financial Results and Business Progress
- Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion